ProMIS Neurosciences initiates Phase 1b trial in Alzheimer’s disease

ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in Alzheimer’s disease, AD. PMN310, a humanized IgG1 antibody, is engineered to selectively target toxic oligomers of amyloid-beta-which are believed to be a key driver of Alzheimer’s pathology-while avoiding interaction with plaque deposits. This mechanism is designed to help reduce the risk of amyloid-related imaging abnormalities, a common side effect associated with existing therapies, potentially offering a differentiated product profile.